secwatch.observer — SEC 8-K summary
======================================

Issuer:     Frazier Life Sciences Acquisition Corp. II (FLSC)
CIK:        0002153598
Form:       8-K
Filed at:   2026-10-15T20:23:55+00:00
Accession:  0001193125-26-422919
Event type: other_material
Sentiment:  neutral
Materiality: 0.35
Item codes: 1.01, 3.02, 5.03, 8.01, 9.01
LLM model:  deepseek-v4.1-flash:cloud@v2

Frazier Life Sciences Acquisition Corp. II closes $75M IPO at $10.00; FLSC lists on Nasdaq
--------------------------------------------------------------------------------

- IPO of 7,500,000 Class A ordinary shares at $10.00 raised $75,000,000 gross; shares began trading on Nasdaq under "FLSC" Oct 14, 2026 and the offering closed Oct 15.
- Sponsor Frazier Life Sciences Holdings II, LLC bought 300,000 private placement shares at $10.00 ($3,000,000); not transferable until 30 days after an initial business combination.
- Forward purchase agreement: Frazier Life Sciences Public Fund, L.P. committed to buy at least 2,500,000 Class A shares at $10.00 ($25,000,000), closing with the business combination.
- $75,000,000 placed in trust at Continental Stock Transfer & Trust; up to $100,000 of interest may pay liquidation costs; combination deadline is 24 months from IPO close.
- Led by CEO Albert Cha, Chairman Ben Palleiko and CBO Kevin Li; intends to target biotechnology; Jefferies was sole book-running manager.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/2153598/000119312526422919/0001193125-26-422919-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/2153598/000119312526422919/d417884d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-422919

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer